Philip Mease

2 months ago | dermatologytimes.com | Maddi Hebebrand |Philip Mease

Recently, Philip Mease, MD, director of rheumatology research at Providence Swedish Medical Center in Seattle, Washington, led a comprehensive qualitative study aimed at understanding the concerns and priorities of psoriatic arthritis (PsA) patients. "What we did in this study was to conduct a series of 3PsA patient focus groups in Seattle, Cleveland, and Washington, DC," Mease explained in an interview with Dermatology Times.

Jan 13, 2025 | acrjournals.onlinelibrary.wiley.com | Philip Mease |M. Elaine Husni |Evan Siegel |Daniel E. Furst

INTRODUCTION Psoriatic arthritis (PsA) is an immune-mediated inflammatory disease that affects up to 30% of patients with psoriasis, which is present in 1% to 3% of the world population, causing a significant disease burden and reduction in health-related quality of life.1 PsA combines the burden of joint and axial inflammation with that of skin involvement and is a complex disease to assess and treat.

Jan 1, 2025 | jrheum.org | Cláudia Goldenstein-Schainberg |Enrique R Soriano |Laura Savage |Philip Mease

The 1st GRAPPA International Meeting on Psoriasis and Psoriatic Arthritis – 1º Encontro Internacional do GRAPPA Sobre Psoríase e Artrite Psoriásica was held on August 18-19, 2023, in São Paulo, Brazil, and marked a turning point in the management of psoriasis (PsO) and psoriatic arthritis (PsA) in our country.

Dec 9, 2024 | the-rheumatologist.org | Philip Mease |George Reed |Alexis Ogdie |Dimitrios A. Pappas |Joel M Kremer

The classic conception of pain etiology in rheumatologic disease is nociceptive pain—tissue injury and inflammation signaling through peripheral and central nerve fibers. But this can be mixed with other pain etiologies, including nociplastic, which is augmented pain experience due to central sensitization. The pain of fibromyalgia (FM) is nociplastic, occurs in 10% to 30% of patients with rheumatologic disease, and its presence can influence disease severity assessment.

Oct 5, 2024 | acrjournals.onlinelibrary.wiley.com | Philip Mease |Xenofon Baraliakos |Rheumazentrum Ruhrgebiet |Vinod Chandran

INTRODUCTION Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease characterized by psoriasis of the skin and nails and joint disease affecting the peripheral and/or axial skeleton.1 Most patients with PsA present with multidomain disease requiring individualized treatment.2 Disease activity, previous therapies, prognostic factors (eg, pre-existing structural damage), comorbid conditions, and patient characteristics may influence response to therapy.3 Considering the...